Perceptions on Expected Outcomes of Immunotherapy in Advanced Non-small Cell Lung Cancer Patients With Poor Performance Status

Study Overview
=================
Brief Summary
-----------------
To better understand your feelings and expectations about immunotherapy

Detailed Description
-----------------
Primary Objective: 1. To compare expectations of survival benefit from immunotherapy between advanced cancer patients with poor performance status (PS) and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of survival beyond 2 years. Secondary Objectives: To compare expectations of therapeutic benefit of immunotherapy between advanced cancer patients with poor PS and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of cure, quality of life improvement, and lower likelihood of adverse events. To qualitatively describe the priorities and preferences for information of advanced cancer patients with poor PS when considering immunotherapy treatment. To evaluate the associations between discrepant expectations with patients' sociodemographic and clinical characteristics. To compare patient and oncologist expectations with actual treatment outcomes and survival.

Official Title
-----------------
Perceptions on Expected Outcomes of Immunotherapy in Advanced Non-small Cell Lung Cancer Patients With Poor Performance Status

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Behavioral: Questionnaires
* Behavioral: Interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients being considered for or within 2 months of starting immunotherapy for advanced cancer Patient ≥18 years of age ECOG ≥2 Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment English speaking Willing to participate in the study and sign informed consent The study will include medical oncologists that treat advanced cancers Exclusion Criteria: Treatment for curative intent Presence of Delirium (as determined by score >13 on MDAS 46, appendix A)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Questionnaires (All Participants)<br>If participants are found to be eligible and agree to take part in the study, information about you (such as age, gender, race, ethnicity, marital status, education, employment status, religious beliefs, and information about your cancer diagnosis and history, current therapy and goal of cancer therapy) will be collected. | Behavioral: Questionnaires<br>* Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires<br>|
| Interview (Some Participants)<br>Not every participant will be asked to have an interview. It is expected that about 20-30 participants will take part in the interview part of the study. | Behavioral: Interview<br>* The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discrepancy in expectation of survival for 2 years or more between the patient and oncologist |  | through study completion; an average of 2 years |